Astel­las taps Po­sei­da for sec­ond CAR-T deal fo­cused on sol­id tu­mors

Astel­las Phar­ma is sign­ing Po­sei­da Ther­a­peu­tics to a sec­ond deal fo­cused on de­vel­op­ing off-the-shelf sol­id tu­mor cell ther­a­pies af­ter the com­pa­nies first teamed up in 2023.

An Astel­las sub­sidiary called Xyphos Bio­sciences plans to use a Po­sei­da CAR-T con­struct to de­vel­op two “con­vert­ible” CAR-T ther­a­py can­di­dates for sol­id tu­mors. Astel­las will pay Po­sei­da $50 mil­lion up­front, with an­oth­er $550 mil­lion in po­ten­tial mile­stone pay­ments. If a ther­a­py is com­mer­cial­ized, Po­sei­da could al­so re­ceive low dou­ble-dig­it roy­al­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER